Published in final edited form as:

Osteoporos Int. 2012 December ; 23(12): 2863–2871. doi:10.1007/s00198-012-1935-8.

Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW)

C. Roux,

Paris Descartes University, Department of Rheumatology, Cochin Hospital, 27 rue du Faubourg St. Jacques, 75659 Paris CEDEX 14, France Tel: +33 1 5841 2579

A. Wyman,

Center for Outcomes Research, UMASS Medical School, Worcester, MA, USA

F. H. Hooven,

Center for Outcomes Research, UMASS Medical School, Worcester, MA, USA

Conflicts of interest Christian Roux—honoraria/consultant/advisory board: Alliance, Amgen, Lilly, Merck, Novartis, Nycomed, Roche, GlaxoSmithKline, Servier, Wyeth.

Allison Wyman: None.

Fred H Hooven—funding: The Alliance for Better Bone Health (sanofi-aventis and Warner Chilcott). Stephen Gehlbach—funding: The Alliance for Better Bone Health (sanofi-aventis and Warner Chilcott).

Jonathan D Adachi—consultant/speaker: Amgen, Lilly, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer, Procter & Gamble, Roche, sanofi-aventis, Servier, Warner Chilcott, Wyeth; clinical trials: Amgen, Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Procter & Gamble, Roche, sanofi-aventis, Warner Chilcott, Wyeth, Bristol-Myers Squibb.

Roland Chapurlat—funding: French Ministry of Health, French Ministry of Research, Merck, Servier, Lilly; honoraria: Amgen, Servier, Novartis, Lilly, Roche; consultant/advisory board: Amgen, Merck, Servier, Novartis.

Juliet E Compston—paid consultancy work: Servier, Shire, Nycomed, Novartis, Amgen, Procter & Gamble, Wyeth, Pfizer, The Alliance for Better Bone Health, Roche, and GlaxoSmithKline; paid speaker and received reimbursement, travel and accommodation: Servier, Procter & Gamble, and Lilly; research grants: Servier R&D and Procter & Gamble.

Cyrus Cooper—consulting fees/lecturer: Amgen, The Alliance for Better Bone Health (sanofi-aventis and Warner Chilcott), Lilly, Merck, Servier, Novartis, Roche-GSK.

Adolfo Díez-Pérez—consulting fees/lecturer: Eli Lilly, Amgen, Procter & Gamble, Servier, Daiichi-Sankyo; expert witness: Merck; consultant/advisory board: Novartis, Eli Lilly, Amgen, Procter & Gamble.

Susan L Greenspan—consultant/advisory board: Amgen, Lilly, Merck; research grants: The Alliance for Better Bone Health (sanofi-aventis and Procter & Gamble), Lilly.

Andrea LaCroix—funding: The Alliance for Better Bone Health (sanofi-aventis and Warner Chilcott); advisory board: Amgen.

J Coen Netelenbos—consultant: Roche Diagnostics, Daiichi-Sankyo, Procter & Gamble, Nycomed; speaker/reimbursement, travel and accommodation: Roche Diagnostics, Novartis, Daiichi-Sankyo, Procter & Gamble; research grants: The Alliance for Better Bone Health, Amgen.

Johannes Pfeilschifter—research grants: Amgen, Kyphon, Novartis, Roche; other research support (equipment): GE Lunar; Speakers' bureau: Amgen, sanofi-aventis, GlaxoSmithKline, Roche, Lilly Deutschland, Orion Pharma, Merck, Merckle, Nycomed, Procter & Gamble; advisory board: Novartis, Roche, Procter & Gamble, Teva.

Maurizio Rossini—Speakers' bureau: Roche, Merck Sharp & Dohme, GlaxoSmithKline.

Kenneth G Saag—consulting fees/other remuneration: Eli Lilly & Co, Merck, Novartis, Amgen; paid research: Eli Lilly & Co, Merck, Novartis, Amgen.

Philip N Sambrook—honoraria/consultant/advisory board: Merck, sanofi-aventis, Roche, Servier.

Stuart Silverman—research grants: Wyeth, Lilly, Novartis, Alliance; Speakers' bureau: Lilly, Novartis, Pfizer, Procter & Gamble; honoraria: Procter & Gamble; consultant/advisory board: Lilly, Amgen, Wyeth, Merck, Roche, Novartis.

Ethel S Siris—consultant: Amgen, Lilly, Novartis, The Alliance for Better Bone Health; Speakers' bureau: Amgen, Lilly.

Nelson B Watts—honoraria: Amgen, Novartis, Warner Chilcott; consultant: Amgen, Arena, Baxter, InteKrin, Johnson & Johnson, Lilly, Medpace, Merck, NPS, Orexigen, Pfizer/Wyeth, Takeda, Vivus, Warner Chilcott; research support: Amgen, Merck, NPS; co-founder/stock options/director: OsteoDynamics.

Steven Boonen—research grants: Amgen, Lilly, Novartis, Pfizer, Procter & Gamble, sanofi-aventis, Roche, GlaxoSmithKline; honoraria/Speakers' bureau/consultant/advisory board: Amgen, Lilly, Merck, Novartis, Procter & Gamble, sanofi-aventis, Servier. Dr Boonen is senior clinical investigator of the Fund for Scientific Research, Flanders, Belgium (F.W.O.-Vlaanderen) and holder of the Leuven University Chair in Metabolic Bone Diseases.

S. H. Gehlbach,

Center for Outcomes Research, UMASS Medical School, Worcester, MA, USA

J. D. Adachi,

St. Joseph's Hospital, McMaster University, Hamilton, ON, Canada

R. D. Chapurlat,

Division of Rheumatology, INSERM UMR 1033, Université de Lyon, Hôpital E. Herriot, Hospices Civils de Lyon, Lyon, France

J. E. Compston,

School of Clinical Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK

C. Cooper,

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

A. Díez-Pérez,

Department of Medicine, Hospital del Mar-IMIM-Autonomous, University of Barcelona, Barcelona, Spain; and RETICEF, ISCIII, Madrid, Spain

S. L. Greenspan,

University of Pittsburgh, Pittsburgh, PA, USA

A. Z. LaCroix,

Fred Hutchinson Cancer Research Center, Seattle, WA, USA

J. C. Netelenbos,

Department of Endocrinology, VU University Medical Center, Amsterdam, The Netherlands

J. Pfeilschifter,

Department of Internal Medicine III, Alfried Krupp Krankenhaus, Essen, Germany

M. Rossini,

Department of Rheumatology, University of Verona, Verona, Italy

K. G. Saag,

University of Alabama-Birmingham, Birmingham, AL, USA

P. N. Sambrook,

University of Sydney-Royal North Shore Hospital, St. Leonards, Sydney, NSW, Australia

S. Silverman,

Department of Rheumatology, Cedars-Sinai/UCLA, Los Angeles, CA, USA

E. S. Siris,

Department of Medicine, Columbia University Medical Center, New York, NY, USA

N. B. Watts, and

Bone Health and Osteoporosis Center, University of Cincinnati, Cincinnati, OH, USA

S. Boonen

Leuven University Center for Metabolic Bone Diseases, Division of Geriatric Medicine, Katholieke Universiteit Leuven, Leuven, Belgium

for the GLOW investigators

C. Roux: christian.roux@cch.ap-hop-paris.fr

Abstract

Purpose—Most fracture studies have focused on hip and vertebral fractures, but there is growing evidence that non-hip, non-vertebral (NHNV) fractures also result in substantial morbidity and healthcare costs. We sought to assess the effect of NHNV fractures on quality of life.

Methods—We analyzed 1-year incidences of hip, spine, major NHNV (pelvis/leg, shoulder/arm) and minor NHNV (wrist/hand, ankle/foot, rib/clavicle) fractures among women from the GLOW registry, a prospective, multinational, observational cohort study. Health-related quality of life (HRQL) was analyzed using EuroQol EQ-5D and the SF-36 health survey.

Results—Among 50,461 women analyzed, there were 1,822 fractures (57% minor NHNV, 26% major NHNV, 10% spine, 7% hip) over 1 year. Spine fractures had the greatest detrimental effect on EQ-5D summary scores, followed by major NHNV and hip fractures. The amount of women with mobility problems increased most for those with major NHNV and spine fractures (both +8%); spine fractures were associated with the largest increases in problems with self care (+11%), activities (+14%), and pain/discomfort (+12%). Decreases in physical function and health status were greatest for women with spine or hip fractures. Multivariable modeling found that EQ-5D reduction was greatest for spine fractures, followed by hip and major/minor NHNV. Significant reductions in SF-36 physical function were found only for spine and major NHNV fractures.

Conclusion—This prospective study shows that NHNV fractures have a detrimental effect on HRQL. As NHNV fractures account for >80% of incident fractures, efforts to optimize osteoporosis care should include prevention of NHNV fractures.

Keywords

Non-hip, non-vertebral fractures; Quality of life; Postmenopausal women

Introduction

The consequences of osteoporotic fractures are increasingly recognized, but most studies have focused on hip and vertebral fractures, and the morbidity and mortality associated with these “typical” fractures. Among the different types of non-vertebral fractures, hip fractures and their clinical and economic impact have received most attention. However, growing evidence suggests that the burden of fractures at other sites (non-hip, non-vertebral [NHNV] fractures) may have been under-recognized [1, 2]. NHNV fractures occur more frequently than clinical spine or hip fractures, and carry an increased risk for subsequent fractures [3–6]. They may have different risk factors than vertebral and hip fractures [7–10] and may result in considerable morbidity and disability. Furthermore, the cost of direct medical care for NHNV fractures may exceed that for hip fracture alone [11, 12]. In a recent study, certain types of NHNV fractures were confirmed to be associated with significant excess mortality [13]. Similarly, the consequences of all types of fractures on health-related quality

of life (HRQL) are well recognized [14–17], although few studies have focused on NHNV fractures [18].

The Global Longitudinal study of Osteoporosis in Women (GLOW) was established to provide a practice-based evaluation of postmenopausal osteoporosis, fractures, and related risk factors. The aims of the current analysis were to measure the 1-year incidence of NHNV fractures in a cohort of older women, and to assess the impact of these fractures on HRQL at 1 year of follow-up.

Methods

The study design of GLOW, a prospective, multinational, observational cohort study, has previously been described in detail [19]. Briefly, women were recruited through 723 primary healthcare physicians in ten countries (Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, UK, and USA). Study sites were selected on the basis of geographic distribution and the presence of lead investigators with expertise in osteoporosis and access to a clinical research team capable of managing a large cohort of subjects. These lead investigators identified primary care practices in their region that were members of local research or administrative networks and were able to supply names and addresses of their patients electronically. The composition of groups varied by region and included health-system owned practices, private practices, independent practice associations, and health maintenance organizations. Participating physicians were defined as those who spent most of their time providing primary healthcare to patients, and included internists, family practitioners, and general practitioners.

Data were obtained using self-administered questionnaires, which were mailed to women aged 55 years, with a 2:1 over-sampling of women 65 years of age. Follow-up questionnaires were sent at 1-year intervals, and this analysis uses data from the baseline and 1-year follow-up surveys. The study questionnaires were used to collect information on demographic characteristics; medical history (including fractures with site, comorbidities); risk factors for fracture occurrence; self-report of prevention, diagnosis, and treatments of osteoporosis; HRQL; and health service access and utilization.

HRQL and functional status were assessed using the EuroQol EQ-5D tool [20] and the vitality and physical function sections of the SF-36 health survey [21]. The EQ-5D is a five-question, three-response option scale that maps each of 243 health states to a country-specific preference-based value or utility, where 1.00 represents full health and 0.00 represents a state equivalent to death. A change of 0.03 is recognized as a minimum clinically important difference in individuals with osteoporosis [22].

Women who responded to the 1-year follow-up survey were divided in subgroups according to fracture occurrence and fracture site: “major” NHNV (pelvis, upper leg, lower leg, shoulder, upper arm, knee, and elbow), “minor” NHNV (wrist, hand, ankle, foot, rib, and clavicle), and hip and vertebral fractures. The definitions of major and minor NHNV were similar to those used by Bliuc et al. [13]: upper leg corresponded to distal femur, lower leg

to proximal tibia, and arm to proximal humerus (including shoulder). Major NHNV fractures were defined as related to an increased risk of mortality [13].

Statistical analysis

Continuous variables are shown as medians with 25th and 75th percentiles, or as means with standard deviations (SDs); percentages are shown for dichotomous variables. Results are shown for incident fracture groups (major, minor, spine, and hip, or by individual fracture type), with the “no fracture” group as a comparison. These categories are not mutually exclusive, as women could have experienced more than one fracture.

To estimate comparative effects of different types of fracture, we performed multiple linear regression analyses predicting 1-year EQ-5D score based on baseline EQ-5D score and fracture group, controlling for a predetermined clinically relevant set of variables. Results are expressed as mean difference in 1-year EQ-5D score with a 95% confidence interval (CI) for that difference. Identical analyses were then performed for the 1-year and baseline SF-36 physical function and vitality scores. All analyses were performed using SAS version 9.2 (SAS Inc., Cary, NC, USA).

Results

There were 51,491 women with both baseline and 1-year follow-up data. Of these, 1,030 women were excluded due to missing incident fracture information, leaving 50,461 women for this analysis.

The number of incident fractures was 1,822 and their distribution is shown in Fig. 1. Of 1,822 incident fractures, 57% were minor NHNV, 26% were major NHNV, 10% were spine, and 7% were hip fractures. The incidence of any fracture was 3.1%, spine fracture 0.4%, and hip fracture 0.3%. The incidence of all NHNV fractures was 2.7%, major NHNV fractures 0.9%, and minor NHNV fractures 2.0%, (Fig. 2). Upper arm, lower leg, upper leg, and pelvis fractures accounted for 93% of major NHNV fractures; and wrist, ankle, and rib fractures made up 91% of minor NHNV fractures. The incidence of fractures according to age groups is shown in Fig. 3.

Table 1 shows median age, age distribution, and risk factors according to the type of incident fracture reported. Women with hip fractures had the highest median age (77 years), followed by women with spine or major NHNV fractures (73 years for both), and minor fractures (69 years). Women with no incident fractures were the youngest, with a median age of 67 years. Median body mass index was similar across the fracture categories, but the proportion of low-weight women in each group increased from 16% in the no-fracture group, to 21% for spine fractures and 25% for hip fractures. Fewer women with major NHNV fractures were low weight (19%), although this was more than for those with minor NHNV fractures (17%) or no fracture.

Unadjusted HRQL measures at baseline and after incident fracture are shown in Table 2. Women with spine fractures experienced the greatest change in their mean EQ-5D summary score, which dropped from 0.65 at baseline to 0.58 after the fracture. Major NHNV fractures

and hip fractures accounted for the next greatest drop in mean EQ-5D (0.70 to 0.66 and 0.64 to 0.60, respectively), followed by minor NHNV fractures (0.72 to 0.70) and no fracture (no change). The change in the percentage of women reporting problems with mobility was greatest for women with major NHNV fractures or spine fractures (+8%). Spine fractures were associated with the greatest increases in problems with self care (+11%), activities (+14%), and pain/discomfort (+12%). Increases in percentages reporting problems with self care and activities were similar for major NHNV fractures (+6% for self care; +10% for activities) and hip fractures (+5% for self care; 10% for activities). Among the different fracture categories, increases in problems reported were lowest for women with minor NHNV fractures. The increase in the percentage of women reporting fair or poor health status was greatest for spine fractures (0.06), then hip and major NHNV fractures (both 0.05). Decrease in physical function was greatest for spine and hip fractures (8 points), while decreases in vitality were the same for major NHNV, hip, and spine fractures (3 points).

Also reported in Table 2 are the proportions of women who reported a decrease in general health status between the baseline and 1-year surveys. The largest proportion of women to report a decrease in health status were those with a fracture of the spine (30%), followed by hip (28%), major NHNV fractures (24%), minor NHNV fractures (21%), and no fracture (19%). An increase in perception of risk of a future fracture at 1-year follow-up compared with baseline was reported by 51% of women with hip fracture, 42% with spine fractures, 40% with major NHNV fractures, 39% with minor NHNV fractures, and 21% with no incident fracture.

Table 3 shows the multivariable model predicting 1-year change based on incident fracture category and controlling for age, comorbidities, and baseline fractures. The reduction in EQ-5D was greatest for spine fractures and hip fractures. The reduction for women with major or minor NHNV fractures was the same. Statistically significant reductions in SF-36 physical function were found for major NHNV fractures and spine fractures only; and in vitality for spine fractures only. The consequences of incident wrist fractures, the most frequent minor NHNV fractures, were weak.

Discussion

Data from cross-sectional studies have previously shown that the effect of NHNV fractures on HRQL is significant. In the Canadian Multicenter Osteoporosis Study, pelvic, lower limbs, and rib fractures were associated with very low HRQL scores [23]. Similarly, assessment of the baseline data of the GLOW study suggested that previous fractures at a variety of locations may be associated with significant reductions in quality of life [24]. Our current prospective incident fracture data confirm and extend the results of these cross-sectional studies. NHNV fractures were found to be the most common incident fractures in women aged 55 years, and both minor and major incident NHNV fractures found to have a strong impact on HRQL over 1 year, independent of baseline HRQL.

A number of studies have reported that NHNV fractures account for the majority of all fractures, up to 90% in people <80 years of age, and 50% thereafter [25, 26]. In a study by Lippuner et al. [27], limb fractures alone contributed to almost one third of all fracture-

related hospital admissions. In line with these findings, NHNV fractures in our study were the most common incident fractures in women aged 55 years. The ratios of NHNV to hip fractures reported by Kanis et al. were 21.1, 6.1, 2.8, and 1.4 in women aged 50, 60, 70, and 80 years, respectively [2]. In our study, approximately one third of NHNV fractures occurred in women aged < 65 years, which may be due to the fact that twice as many women 65 years were enrolled as those aged <65 years. NHNV fractures typically occurred at younger ages than vertebral and hip fractures, but their burden in our population was still dramatically high in women after the age of 70 years. For each 10-year span of age, we found the incidence of NHNV fractures to be 10-fold greater than the incidence of vertebral or hip fractures.

In addition to the effect of age and age-related determinants of fracture risk, the underlying increase in the risk of falls and decrease in bone density with age are both likely to play a major role in this high incidence of NHNV fractures. Annual fall prevalence increases with age, and NHNV fractures almost inevitably result from falls [28]. Similarly, the risk of almost all NHNV fractures is associated with low bone mineral density (BMD) [29]. Low femoral neck or hip BMD is associated with increased risk of humerus, forearm, and wrist fractures [10, 30]. Thus, beyond falls, a number of bone parameters (DXA T score and prevalent vertebral and non-vertebral fractures) can be used to assess the risk of such fractures in postmenopausal women [29, 31].

One of our key findings in women aged 55 years is that both minor and major incident NHNV fractures have a strong impact on HRQL as measured by EQ-5D over 1 year, independent of baseline HRQL. Women with incident major NHNV fractures also reported statistically significant reductions in HRQL following fracture as measured by SF-36 physical function index. Reductions in EQ-5D and SF-36 physical functioning for women with major NHNV fractures were of a similar magnitude to reductions for women with incident hip fractures, but lower than for women who experienced incident spine fractures.

The physical function limitations and reduced HRQL among the younger women in our study could have a major impact on the number of working days lost. In fact, Fink et al. documented significant disability, as reflected by days hospitalized or confined to bed and days of reduced usual activities, because of a fracture ("limited activity days") in women with humerus, ankle, or distal forearm fracture [27]. In our multivariable analysis, women with spine fractures showed the greatest reductions in EQ-5D and SF-36 physical function and vitality scores. Although the magnitude of the change in HRQL for NHNV fractures was lower than for hip and spine fractures, it should be noted that fractures of the pelvis, upper leg, lower leg, shoulder, upper arm, knee, and elbow accounted for 26% of all incident fractures. In contrast, hip and spine fractures represented 18% of all incident fractures. The substantial number of NHNV fractures in this population, combined with the significant negative impact on HRQL has important clinical implications. As a group, these fractures are associated with significant suffering, particularly in older women, and more attention to the effects of these fractures is urgently needed.

Incident wrist fractures had little impact on HRQOL, and no effect on SF36 physical function or vitality. This confirms previous results [32] with the exception of studies which

assessed the effect of wrist fracture in relation to specific tasks involving upper limb function [33, 34]. Other studies have shown that functional recovery after a wrist fracture is completed by 6 months [30]. Our data do not suggest that, at the age of 69 years on average, wrist fracture contributes to functional decline, although we did not ask women specifically about decline in upper limb function.

Our study has some important limitations, as well as a number of strengths. Fractures were self-reported and were not confirmed radiographically. Self-report has been shown to be accurate for hip and wrist fractures, though less so for fractures of the spine [35]. We cannot confirm the diagnosis of vertebral fractures, as they were self-reported. Most vertebral fractures are not recognized, and even asymptomatic vertebral deformities could impact on daily living activities and HRQL [16]. Most studies that include vertebral fracture as an outcome will therefore underestimate the incidence of vertebral fractures and their effect on HRQL. To the extent that there is error in the reporting of other NHNV fractures, our estimates of HRQL would also be biased toward the null.

The effect of prevalent (at baseline) fractures in this study may have been attenuated by the absence of information on the time of occurrence. Had we been able to adjust for the recent timing of these fractures, we might have detected a stronger effect on HRQL for women with both a prevalent and incident fracture. Among the strengths of our study are the prospective design, the international nature of the sample, and the fact that data were collected in the same way, using the same survey questions, in all countries. We recognize, however, that while women from 10 countries are included in the cohort, these results may not be generalizable to non-western countries. The large sample size is also a strength, as few studies have had adequate statistical power to assess, prospectively, the consequences of incident NHNV fractures on HRQL.

Conclusion

In conclusion, our study demonstrates the detrimental impact of NHNV fractures on HRQL. Efforts to optimize the care of patients with osteoporosis should not be focused solely on hip and spine fractures; rather, treatment strategies should include the prevention of NHNV fractures.

Acknowledgments

We thank the physicians and study coordinators participating in GLOW, the staff at the Center for Outcomes Research, including Linda Chase and Sophie Rushton-Smith, PhD.

Funding

Financial support for the GLOW study is provided by Warner Chilcott Company, LLC and sanofi-aventis to the Center for Outcomes Research, University of Massachusetts Medical School.

References

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int*. 2006; 17:1726–1733. [PubMed: 16983459]

2. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. *Osteoporos Int.* 2001; 12:417–427. [PubMed: 11444092]
3. Cuddihy MT, Gabriel SE, Crowson CS, O'Fallon WM, Melton LJ 3rd. Forearm fractures as predictors of subsequent osteoporotic fractures. *Osteoporos Int.* 1999; 9:469–475. [PubMed: 10624452]
4. Huntjens KM, Kosar S, van Geel TA, Geusens PP, Willems P, Kessels A, Winkens B, Brink P, van Helden S. Risk of subsequent fracture and mortality within 5 years after a non-vertebral fracture. *Osteoporos Int.* 2010; 21:2075–2082. [PubMed: 20162259]
5. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. *J Bone Miner Res.* 2000; 15:721–739. [PubMed: 10780864]
6. Lauritzen JB, Schwarz P, McNair P, Lund B, Transbol I. Radial and humeral fractures as predictors of subsequent hip, radial or humeral fractures in women, and their seasonal variation. *Osteoporos Int.* 1993; 3:133–137. [PubMed: 8481589]
7. Finigan J, Greenfield DM, Blumsohn A, Hannon RA, Peel NF, Jiang G, Eastell R. Risk factors for vertebral and nonvertebral fracture over 10 years: a population-based study in women. *J Bone Miner Res.* 2008; 23:75–85. [PubMed: 17784843]
8. Graafmans WC, Ooms ME, Bezemer PD, Bouter LM, Lips P. Different risk profiles for hip fractures and distal forearm fractures: a prospective study. *Osteoporos Int.* 1996; 6:427–431. [PubMed: 9116386]
9. Honkanen R, Tuppurainen M, Kroger H, Alhava E, Saarikoski S. Relationships between risk factors and fractures differ by type of fracture: a population-based study of 12,192 perimenopausal women. *Osteoporos Int.* 1998; 8:25–31. [PubMed: 9692074]
10. Nguyen TV, Center JR, Sambrook PN, Eisman JA. Risk factors for proximal humerus, forearm, and wrist fractures in elderly men and women: the Dubbo Osteoporosis Epidemiology Study. *Am J Epidemiol.* 2001; 153:587–595. [PubMed: 11257067]
11. Pike C, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET. Economic burden of privately insured non-vertebral fracture patients with osteoporosis over a 2-year period in the US. *Osteoporos Int.* 2011; 22:47–56. [PubMed: 20490782]
12. Ray NF, Chan JK, Thamer M, Melton LJ 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. *J Bone Miner Res.* 1997; 12:24–35. [PubMed: 9240722]
13. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. *JAMA.* 2009; 301:513–521. [PubMed: 19190316]
14. Adachi JD, Loannidis G, Berger C, Joseph L, Papaioannou A, Pickard L, Papadimitropoulos EA, Hopman W, Poliquin S, Prior JC, Hanley DA, Olszynski WP, Anastassiades T, Brown JP, Murray T, Jackson SA, Tenenhouse A. The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. *Osteoporos Int.* 2001; 12:903–908. [PubMed: 11804016]
15. Dennison EM, Jameson KA, Syddall HE, Martin HJ, Cushnaghan J, Aihie Sayer A, Cooper C. Bone health and deterioration in quality of life among participants from the Hertfordshire cohort study. *Osteoporos Int.* 2010; 21:1817–1824. [PubMed: 20024529]
16. Fechtenbaum J, Cropet C, Kolta S, Horlait S, Orcel P, Roux C. The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. *Osteoporos Int.* 2005; 16:2175–2179. [PubMed: 16220230]
17. Hallberg I, Rosenqvist AM, Kartous L, Lofman O, Wahlstrom O, Toss G. Health-related quality of life after osteoporotic fractures. *Osteoporos Int.* 2004; 15:834–841. [PubMed: 15045468]
18. Dolan P, Torgerson D, Kakarlapudi TK. Health-related quality of life of Colles' fracture patients. *Osteoporos Int.* 1999; 9:196–199. [PubMed: 10450406]
19. Hooven FH, Adachi JD, Adami S, Boonen S, Compston J, Cooper C, Delmas P, Diez-Perez A, Gehlbach S, Greenspan SL, LaCroix A, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Sambrook P, Silverman S, Siris E, Watts NB, Anderson FA Jr. The Global Longitudinal Study

- of Osteoporosis in Women (GLOW): rationale and study design. *Osteoporos Int.* 2009; 20:1107–1116. [PubMed: 19468663]
20. EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group. *Health Policy.* 1990; 16:199–208. [PubMed: 10109801]
 21. Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. *BMJ.* 1992; 305:160–164. [PubMed: 1285753]
 22. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. *Med Care.* 2005; 43:736–749. [PubMed: 15970790]
 23. Adachi JD, Ioannidis G, Pickard L, Berger C, Prior JC, Joseph L, Hanley DA, Olszynski WP, Murray TM, Anastassiades T, Hopman W, Brown JP, Kirkland S, Joyce C, Papaioannou A, Poliquin S, Tenenhouse A, Papadimitropoulos EA. The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). *Osteoporos Int.* 2003; 14:895–904. [PubMed: 12920507]
 24. Adachi JD, Adami S, Gehlbach S, Anderson FA Jr, Boonen S, Chapurlat RD, Compston JE, Cooper C, Delmas P, Diez-Perez A, Greenspan SL, Hooven FH, LaCroix AZ, Lindsay R, Netelenbos JC, Wu O, Pfeilschifter J, Roux C, Saag KG, Sambrook PN, Silverman S, Siris ES, Nika G, Watts NB. Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. *Mayo Clin Proc.* 2010; 85:806–813. [PubMed: 20634496]
 25. Kannus P, Sievanen H, Palvanen M, Jarvinen T, Parkkari J. Prevention of falls and consequent injuries in elderly people. *Lancet.* 2005; 366:1885–1893. [PubMed: 16310556]
 26. Melton LJ 3rd, Crowson CS, O’Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. *Osteoporos Int.* 1999; 9:29–37. [PubMed: 10367027]
 27. Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. *Osteoporos Int.* 2005; 16(Suppl 2):S8–S17. [PubMed: 15378232]
 28. Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Nevitt MC, Cummings SR. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. *J Bone Miner Res.* 2003; 18:1947–1954. [PubMed: 14606506]
 29. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. *Osteoporos Int.* 2001; 12:989–995. [PubMed: 11846333]
 30. Fink HA, Ensrud KE, Nelson DB, Kerani RP, Schreiner PJ, Zhao Y, Cummings SR, Nevitt MC. Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT). *Osteoporos Int.* 2003; 14:69–76. [PubMed: 12577187]
 31. Roux C, Briot K, Horlait S, Varbanov A, Watts NB, Boonen S. Assessment of non-vertebral fracture risk in postmenopausal women. *Ann Rheum Dis.* 2007; 66:931–935. [PubMed: 17314119]
 32. Brenneman SK, Barrett-Connor E, Sajjan S, Markson LE, Siris ES. Impact of recent fracture on health-related quality of life in postmenopausal women. *J Bone Miner Res.* 2006; 21:809–816. [PubMed: 16753011]
 33. Edwards BJ, Song J, Dunlop DD, Fink HA, Cauley JA. Functional decline after incident wrist fractures--Study of Osteoporotic Fractures: prospective cohort study. *BMJ.* 2010; 341:c3324. [PubMed: 20616099]
 34. Greendale GA, Barrett-Connor E, Ingles S, Haile R. Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study. *J Am Geriatr Soc.* 1995; 43:955–961. [PubMed: 7657934]
 35. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ. The accuracy of self-reported fractures in older people. *J Clin Epidemiol.* 2002; 55:452–457. [PubMed: 12007547]

Fig. 1. Distribution of incident fracture types. *Major NHNV* pelvis, upper leg, lower leg, shoulder, upper arm, knee, and elbow; *minor NHNV* wrist, hand, ankle, foot, rib, and clavicle.

Fig. 2.
Distribution of incident fracture types. *NHHV* non-hip, non-vertebral.

Fig. 3.
One-year incidence of fractures in GLOW by age group.

Table 1

Characteristics of the study population ($n=50,461$).

	Incident fracture type				
	No fracture ($n=48,887$)	Major $NHNV^a$ ($n=448$)	Minor $NHNV^b$ ($n=982$)	Spine ($n=178$)	Hip ($n=126$)
Median age, years (IQR)	67 (61, 74)	73 (63, 79)	69 (62, 77)	73 (66, 81)	77 (71, 83)
Median BMI (IQR)	26 (23, 30)	26 (23, 30)	26 (23, 30)	25 (22, 28)	25 (22, 28)
Age group, %					
<65 years	39	27	34	20	13
65–74 years	36	29	35	33	26
75–84 years	20	32	25	36	40
85 years	4.3	11	6.0	11	20
Risk factors for fracture, %					
Weight <125 lbs [<57 kg]	16	19	17	21	25
Baseline fracture	22	50	43	56	52
Parental history of hip fracture	17	21	21	23	25
Current baseline cigarette use	8.6	10	9.9	11	7.3
Current baseline cortisone use	2.9	5.9	5.3	9.7	4.0
Secondary osteoporosis risk factors ^c	21	23	27	25	23
Alcohol >20 drinks/week	0.5	0.2	0.9	0.6	0.8

BMI body mass index, *IQR* interquartile range, *NHNV* non-hip, non-vertebral.

^aMajor fractures: pelvis, upper leg, lower leg, shoulder, upper arm, knee, and elbow.

^bMinor fractures: wrist, hand, ankle, foot, rib, and clavicle.

^cBaseline use of anastrozole, exemestane, or letrozole; baseline diagnosis of celiac disease, ulcerative colitis/Crohn's disease, or Type I diabetes; or menopause before age 45 years.

Table 2

Comparison of HRQL, functional status, and vitality measures according to incident fracture status ($n=50,461$)

	Incident fracture type									
	No fracture (<i>n</i> =48,887)		Major NHNV ^a (<i>n</i> =448)		Minor NHNV ^b (<i>n</i> =982)		Spine (<i>n</i> =178)		Hip (<i>n</i> =126)	
	Baseline	Year 1	Baseline	Year 1	Baseline	Year 1	Baseline	Year 1	Baseline	Year 1
EQ-5D										
Mean summary score (SE)	0.78 (0.001)	0.78 (0.001)	0.70 (0.01)	0.66 (0.01)	0.72 (0.01)	0.70 (0.01)	0.65 (0.02)	0.58 (0.02)	0.64 (0.03)	0.60 (0.03)
Domains, problems with, %										
Mobility	27	26	46	54	38	41	48	56	57	63
Self care	5.5	6.4	17	23	11	16	17	28	23	28
Activities	26	27	44	54	39	42	52	66	57	67
Pain/discomfort	68	68	76	79	75	79	78	90	78	86
Anxiety/depression	40	41	47	49	49	49	54	58	54	54
SF-36 subscales, %										
Perception of fracture risk										
Increase	–	21	–	40	–	39	–	42	–	51
Decrease	–	23	–	13	–	12	–	11	–	12
Same	–	56	–	47	–	49	–	46	–	37
General health status fair/poor	21	22	37	42	33	35	44	50	40	45
Health status change										
Increase	–	17	–	19	–	18	–	14	–	18
Decrease	–	19	–	24	–	21	–	30	–	28
Same	–	64	–	57	–	60	–	56	–	55
Mean physical function (SE)	74 (0.12)	73 (0.12)	61 (1.5)	55 (1.6)	65 (0.94)	62 (1.0)	58 (2.4)	50 (2.3)	54 (2.8)	46 (2.8)
Mean vitality (SE)	61 (0.09)	61 (0.09)	55 (1.1)	52 (1.1)	55 (0.70)	54 (0.75)	50 (1.7)	47 (1.7)	52 (2.0)	49 (2.2)

HRQL health-related quality of life, NHNV non-hip non-vertebral, SE standard error.

^aMajor fractures: pelvis, upper leg, lower leg, shoulder, upper arm, knee, and elbow.^bMinor fractures: wrist, hand, ankle, foot, rib, and clavicle.

Table 3

Multivariable models predicting adjusted mean difference in HRQL, functional status, and vitality at 1 year

		Incident fracture type					
	No fracture ^a (n=48,887)	Major NHNV ^{b,c} (n=448)	Minor NHNV ^{b,d} (n=632)	Wrist ^b (n=380)	Spine ^b (n=178)	Hip ^b (n=126)	
EQ-5D (n=45,904)							
Mean difference	0.04	-0.06	-0.06	-0.04	-0.11	-0.07	
95% CI	(0.03, 0.05)	(-0.09, -0.02)	(-0.10, -0.02)	(-0.8, 0.001)	(-0.16, -0.06)	(-0.13, -0.02)	
SF-36 physical function (n=49,441)							
Mean difference	4.1	-3.8	-0.3	3.3	-5.4	-4.2	
95% CI	(3.3, 5.0)	(7.7, 0.4)	(-4.3, 3.6)	(-0.9, 7.5)	(-10, -0.7)	(-9.7, 1.2)	
SF-36 vitality (n=48,952)							
Mean difference	2.7	-1.5	-1.8	-0.2	-4.5	-1.6	
95% CI	(1.9, 3.5)	(-4.7, 1.7)	(-5.0, 1.4)	(-3.6, -3.2)	(-8.4, 0.5)	(-6.1, 2.9)	

CI confidence interval, *HRQL* health-related quality of life, *NHNV* non-hip non-vertebral.

^aModel covariates: no incident fracture; baseline EQ-5D [or SF-36 vitality or physical function, to match the outcome]; age; baseline diagnosis of lung disease, heart disease, cancer, or osteoarthritis; number of baseline fractures; major NHNV baseline fracture; minor NHNV baseline fracture; baseline hip fracture; baseline spine fracture.

^bModel covariates: major NHNV incident fracture; minor NHNV incident fracture; incident spine fracture; incident hip fracture; baseline EQ-5D [or SF-36 vitality or physical function, to match the outcome]; age; baseline diagnosis of lung disease, heart disease, cancer, or osteoarthritis; number of baseline fractures; major NHNV baseline fracture; minor NHNV baseline fracture; baseline hip fracture; baseline spine fracture; days from incident fracture and EQ-5D assessment.

^cMajor fractures: pelvis, upper leg, lower leg, shoulder, upper arm, knee, and elbow.

^dMinor fractures: hand, ankle, foot, rib, and clavicle.